Aktis Oncology, Inc., a clinical-stage oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for patient populations not addressed by existing platform technologies, today announced the appointment of Mr. Kyle Kuvalanka as Chief Financial Officer (CFO). The appointment strengthens Aktis’ financial and corporate development leadership as the Company advances its clinical pipeline and corporate growth initiatives.
